Results 161 to 170 of about 3,407,318 (341)

Association between diabetes and in‐hospital outcomes in patients with metabolic dysfunction‐associated steatotic liver disease hospitalized for cardiovascular disease: A nationwide database study

Diabetic Medicine, EarlyView.
In a nationwide cohort of 10,614 patients with metabolic dysfunction–associated steatotic liver disease (MASLD) hospitalized for cardiovascular disease (CVD), diabetes was present in 4550 patients (43%) and was independently associated with higher in‐hospital mortality and cardiovascular complications.
Soichi Komaki, Michikazu Nakai, Yunosuke Matsuura, Kinuko Yamamoto, Hiroki Tanaka, Yuri Komaki, Masashi Yamaguchi, Kohei Moribayashi, Takeshi Ideguchi, Hiroshi Kawakami, Toshihiro Tsuruda, Koichi Kaikita   +11 more
wiley   +1 more source

Synthesis and Biological Evaluation of Novel Thiadiazole Derivatives as Antiplatelet Agents. [PDF]

Iran J Pharm Res, 2023
Khakpash M, Esfahanizadeh M, Mahboubi-Rabbani M, Amidi S, Kobarfard F.   +4 more
europepmc   +1 more source

Comparison of cardiovascular outcomes between once‐weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims This study aims to compare the risk of major adverse cardiovascular events (MACE) among United States individuals with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD) treated with once‐weekly semaglutide vs. dulaglutide.
Xi Tan, Yuanjie Liang, Lin Xie, Joanna Harton, Cynthia Gutierrez, Chalak Muhammad, Caroline Swift, Adam de Havenon   +7 more
wiley   +1 more source

Preparation and Evaluation of 6-Gingerol Derivatives as Novel Antioxidants and Antiplatelet Agents. [PDF]

Antioxidants (Basel), 2023
Ahmed SHH, Gonda T, Agbadua OG, Girst G, Berkecz R, Kúsz N, Tsai MC, Wu CC, Balogh GT, Hunyadi A.   +9 more
europepmc   +1 more source

Risk of acute pancreatitis with DPP‐4 inhibitors versus SGLT2 inhibitors in medication‐naïve individuals with diabetes: A target trial emulation

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims We investigated whether dipeptidyl peptidase‐4 inhibitor (DPP‐4i) use was associated with a higher risk of acute pancreatitis compared with sodium–glucose cotransporter 2 inhibitor (SGLT2i) use in antidiabetic medication‐naïve individuals.
Takashi Tatewaki, Akira Okada, Yuya Kimura, Hideo Yasunaga   +3 more
wiley   +1 more source

Novel Antithrombotic Agents in Pregnancy Anticoagulants and Antiplatelet Agents. [PDF]

Clin Obstet Gynecol, 2023
James AH, Sugrue R, Federspiel JJ.
europepmc   +1 more source

Polycythemia Vera and Essential Thrombocythemia: A Nationwide Population‐Based Study on Treatment Patterns, Vascular Complications and Survival

European Journal of Haematology, EarlyView.
ABSTRACT Background Polycythemia vera (PV) and essential thrombocythemia (ET) are associated with a well‐recognized increased risk of thrombotic events, bleeding, and all‐cause mortality, but the frequency of these outcomes during treatment has rarely been assessed in large cohorts.
Anneli Enblom Larsson, Henrik Renlund, Björn Andréasson, Henrik Holmberg, Maria Liljeholm, Anders Själander   +5 more
wiley   +1 more source

Cardiovascular involvement in Kawaski Disease [PDF]

, 2005
This article contains a case report of a 19 month old child with Kawasaki Disease who developed bilateral giant coronary artery aneurysms.peer ...
Chintala, Kavitha, Forbes, T.J., Reddy, S.V.   +2 more
core  

TGFβ enhances platelet–breast‐cancer‐cell interaction and promotes platelet aggregation

The FEBS Journal, EarlyView.
TGFβ stimulation promotes EMT in MCF7 cells, increasing their ability to bind, activate, and aggregate PLT. This effect involves the upregulation of adhesion molecules Integrin‐αv and Galectin‐3. Inhibiting Integrin‐αv or Galectin‐3, through Cilengitide and GB1103, reduces PLT adhesion to MCF7 and PLT aggregation, suggesting a mechanism linking TGFβ ...
Margherita Genitoni, Lucia Merolle, Agnese Razzoli, Eleonora Maurizi, Gaia Gavioli, Roberto Baricchi, Chiara Marraccini, Davide Schiroli   +7 more
wiley   +1 more source

Antiplatelet agents for chronic kidney disease. [PDF]

Cochrane Database Syst Rev, 2022
Natale P, Palmer SC, Saglimbene VM, Ruospo M, Razavian M, Craig JC, Jardine MJ, Webster AC, Strippoli GF.   +8 more
europepmc   +1 more source